Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher F Claiborne

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 7, 2006
Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonistsTricia J Vos, Suresh Balani, Christopher Blackburn, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R)Thomas H Marsilje, Jonathan B Roses, Emily F Calderwood, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2007
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonistsKevin T Nguyen, Christopher F Claiborne, John A McCauley, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2010
Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channelDouglas C Beshore, Nigel J Liverton, Charles J McIntyre, et al.
Journal of Medicinal Chemistry|March 19, 2004
Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse modelTricia J Vos, Andrei Caracoti, Jennifer L Che, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A InhibitorsTodd B Sells, Ryan Chau, Jeffrey A Ecsedy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2011
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assaysMark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, et al.
Journal of Medicinal Chemistry|January 26, 2007
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonistNigel J Liverton, Rodney A Bednar, Bohumil Bednar, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseMark G Manfredi, Jeffrey A Ecsedy, Kristan A Meetze, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Orally efficacious NR2B-selective NMDA receptor antagonistsChristopher F Claiborne, John A McCauley, Brian E Libby, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry Letters|February 7, 2006
Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonistsTricia J Vos, Suresh Balani, Christopher Blackburn, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R)Thomas H Marsilje, Jonathan B Roses, Emily F Calderwood, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2007
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonistsKevin T Nguyen, Christopher F Claiborne, John A McCauley, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2010
Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channelDouglas C Beshore, Nigel J Liverton, Charles J McIntyre, et al.
Journal of Medicinal Chemistry|March 19, 2004
Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse modelTricia J Vos, Andrei Caracoti, Jennifer L Che, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A InhibitorsTodd B Sells, Ryan Chau, Jeffrey A Ecsedy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2011
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assaysMark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, et al.
Journal of Medicinal Chemistry|January 26, 2007
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonistNigel J Liverton, Rodney A Bednar, Bohumil Bednar, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseMark G Manfredi, Jeffrey A Ecsedy, Kristan A Meetze, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Orally efficacious NR2B-selective NMDA receptor antagonistsChristopher F Claiborne, John A McCauley, Brian E Libby, et al.
Pageof 2